Literature DB >> 21601533

Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.

Jasmina I Ivanova1, Howard G Birnbaum, Matt Schiller, Evan Kantor, Bryan M Johnstone, Ralph W Swindle.   

Abstract

BACKGROUND CONTEXT: Treatment guidelines suggest that most acute low back pain (LBP) episodes substantially improve within a few weeks and that immediate use of imaging and aggressive therapies should be avoided.
PURPOSE: Assess the actual practice patterns of imaging, noninvasive therapy, medication use, and surgery in patients with LBP, and compare their costs to those of matched controls without LBP. STUDY
DESIGN: A retrospective analysis of claims data from 40 self-insured employers in the United States. PATIENT SAMPLE: The study sample included 211,551 patients, aged 18 to 64 years, with one LBP diagnosis or more (per Healthcare Effectiveness Data and Information Set specification) during 2004 to 2006, identified from a claims database. Patients had continuous eligibility for 12 months or more after their index LBP diagnosis (study period), for 6 months or more before their index diagnosis (baseline period), and no other LBP diagnosis during the baseline period. Patients with LBP were matched to a random cohort of patients without LBP by age, gender, employment status, and index year. OUTCOMES MEASURES: Physiological measures (eg, imaging and diagnostic tests), functional measures (eg, pharmacologic and nonpharmacologic treatment for LBP, health-care resource use), and direct (medical and prescription drug) and indirect (disability and medically related absenteeism) costs were assessed within the year after the LBP diagnosis.
METHODS: Univariate analyses described treatment patterns and compared baseline characteristics and study period costs.
RESULTS: Patients with LBP had significantly higher rates of baseline comorbidities and resource use compared with controls. Of patients with LBP, 41.6% had imaging mean (median) [standard deviation] 34.3 (0) [78.6] days after the LBP diagnosis. Most patients with LBP (69.4%) used medications starting 51.9 (8) [86.2] days after the diagnosis. Opioids were commonly prescribed early (41.6% of patients; after 82.8 (25) [105.9] days). Of patients with LBP, 2.05% had surgery during the study period. Patients with LBP were likely to have chiropractic treatment first, followed by pharmacotherapy with muscle relaxants and nonsteroidal anti-inflammatory drugs. Except for less surgery, these findings also held for patients with only nonspecific LBP. Patients with LBP had higher mean direct costs compared with controls ($7,211 vs. $2,382, respectively; p<.0001), with surgery patients having mean direct costs of $33,931.
CONCLUSIONS: Contrary to clinical guidelines, many patients with LBP start incurring significant resource use and associated expenses soon after the index diagnosis. Achieving guideline-concordant care will require substantial changes in LBP practice patterns.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21601533     DOI: 10.1016/j.spinee.2011.03.017

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  85 in total

1.  Abnormal performance of cervical stabilizer muscles in individuals with low back pain.

Authors:  Chattrachoo Thongprasert; R Kanlayanaphotporn
Journal:  J Man Manip Ther       Date:  2018-12-24

2.  Factors Influencing Long-Term Opioid Use Among Opioid Naive Patients: An Examination of Initial Prescription Characteristics and Pain Etiologies.

Authors:  Anuj Shah; Corey J Hayes; Bradley C Martin
Journal:  J Pain       Date:  2017-07-13       Impact factor: 5.820

Review 3.  Conservative spine care: opportunities to improve the quality and value of care.

Authors:  Thomas M Kosloff; David Elton; Stephanie A Shulman; Janice L Clarke; Alexis Skoufalos; Amanda Solis
Journal:  Popul Health Manag       Date:  2013-08-21       Impact factor: 2.459

4.  Analgesic Effects Evoked by Real and Imagined Acupuncture: A Neuroimaging Study.

Authors:  Jin Cao; Yiheng Tu; Scott P Orr; Courtney Lang; Joel Park; Mark Vangel; Lucy Chen; Randy Gollub; Jian Kong
Journal:  Cereb Cortex       Date:  2019-07-22       Impact factor: 5.357

Review 5.  Opioids for low back pain.

Authors:  Richard A Deyo; Michael Von Korff; David Duhrkoop
Journal:  BMJ       Date:  2015-01-05

6.  Beware of the Film Findings!: Low Back Pain Patients and Healthy Volunteers Have A Similar X-Ray Appearance.

Authors:  Roger P Jackson; Travis J Rump; Anne C McManus; Jill A Moore; Andy S Lee
Journal:  Mo Med       Date:  2017 Jan-Feb

7.  The Association Between the Supply of Nonpharmacologic Providers, Use of Nonpharmacologic Pain Treatments, and High-risk Opioid Prescription Patterns Among Medicare Beneficiaries With Persistent Musculoskeletal Pain.

Authors:  Ruchir N Karmali; Asheley C Skinner; Justin G Trogdon; Morris Weinberger; Steven Z George; Kristen Hassmiller Lich
Journal:  Med Care       Date:  2020-05       Impact factor: 2.983

8.  Associations of Early Opioid Use With Patient-reported Outcomes and Health Care Utilization Among Older Adults With Low Back Pain.

Authors:  Laura S Gold; Ryan N Hansen; Andrew L Avins; Zoya Bauer; Bryan A Comstock; Richard A Deyo; Patrick J Heagerty; Sean D Rundell; Pradeep Suri; Judith A Turner; Jeffrey G Jarvik
Journal:  Clin J Pain       Date:  2018-04       Impact factor: 3.442

9.  Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial.

Authors:  Donna M Urquhart; Anita E Wluka; Maurits van Tulder; Stephane Heritier; Andrew Forbes; Chris Fong; Yuanyuan Wang; Malcolm R Sim; Stephen J Gibson; Carolyn Arnold; Flavia M Cicuttini
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873

10.  A Description and Comparison of Treatments for Low Back Pain in the United States.

Authors:  Elizabeth Salt; Yevgeniya Gokun; Anna Rankin Kerr; Jeffery Talbert
Journal:  Orthop Nurs       Date:  2016 Jul-Aug       Impact factor: 0.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.